Latest | F'cast | |
---|---|---|
Div Yield | 0.0% | 0.0% |
Div Cover | n/a | n/a |
Op Mrgn | -358.6% | n/a |
ROCE | n/a |
Latest | F'cast | |
---|---|---|
P/E | n/a | n/a |
PEG | n/a | n/a |
Pr/Revenue | 8.6 | n/a |
Pr/Book | 8.3 |
Latest | F'cast | |
---|---|---|
Revenue | -50.9% | n/a |
PBT | n/a | n/a |
EPS | n/a | n/a |
DPS | n/a | n/a |
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
30-Jun-21 | 1.60 | (2.91) | (3.92)p | n/a | n/a | n/a | n/a | 0.0% |
30-Jun-22 | 4.04 | (2.64) | (3.24)p | n/a | n/a | n/a | n/a | 0.0% |
30-Jun-23 | 1.75 | (8.30) | (11.35)p | n/a | n/a | n/a | n/a | 0.0% |
30-Jun-24 | 0.86 | (3.14) | (0.71)p | n/a | n/a | n/a | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
Alzheimer’s test advanced and royalty agre... | 06-May-2025 | 07:00 | RNS |
Licensing agreed for Optimer as vaccine adjuvant | 30-Apr-2025 | 07:00 | RNS |
Interim Results | 11-Mar-2025 | 07:00 | RNS |
No deals were found in the last 28 days.
Currency | UK Pounds |
Share Price | 0.37p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 0.85 |
52 Week Low | 0.21 |
Volume | 1,629,157 |
Shares Issued | 1,991.34m |
Market Cap | £7.37m |
Beta | 0.01 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
No dividends found |
Time | Volume / Share Price |
16:07 | 29,695 @ 0.37p |
16:02 | 137,674 @ 0.37p |
14:28 | 26,088 @ 0.38p |
12:15 | 65,189 @ 0.38p |
11:58 | 512 @ 0.39p |
CEO | Arron Tolley |
CFO | Andrew Rapson |
You are here: research